Goldman Sachs Group Inc Geron Corp Transaction History

Goldman Sachs Group Inc

$780 Billion
Q3 2025

A detailed history of Goldman Sachs Group Inc transactions in Geron Corp stock. As of the latest transaction made, Goldman Sachs Group Inc holds 21,307,395 shares of GERN stock, worth $23.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,307,395

Previous 9,815,660 117.08%

Holding current value

$23.9 Million

Previous $13.8 Million 110.92%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$1.1 - $1.47 $12.6 Million - $16.9 Million	11,491,735 Added 117.08%	21,307,395 $29.2 Million
Q2 2025 Aug 14, 2025	BUY	$1.18 - $1.62 $1.98 Million - $2.72 Million	1,679,460 Added 20.64%	9,815,660 $13.8 Million
Q1 2025 May 09, 2025	SELL	$1.59 - $3.6 $8.7 Million - $19.7 Million	-5,473,951 Reduced 40.22%	8,136,200 $12.9 Million
Q4 2024 Feb 11, 2025	SELL	$3.3 - $4.44 $14.3 Million - $19.2 Million	-4,330,822 Reduced 24.14%	13,610,151 $48.2 Million
Q3 2024 Nov 14, 2024	BUY	$4.17 - $4.99 $27.7 Million - $33.2 Million	6,643,294 Added 58.8%	17,940,973 $81.5 Million
Q2 2024 Aug 13, 2024	BUY	$3.1 - $5.09 $21.4 Million - $35.2 Million	6,906,997 Added 157.31%	11,297,679 $47.9 Million
Q1 2024 May 15, 2024	BUY	$1.75 - $3.44 $2.12 Million - $4.16 Million	1,210,279 Added 38.05%	4,390,682 $14.5 Million
Q4 2023 Feb 13, 2024	SELL	$1.74 - $2.31 $589,962 - $783,226	-339,059 Reduced 9.63%	3,180,403 $6.71 Million
Q3 2023 May 14, 2024	BUY	$2.11 - $3.28 $715,414 - $1.11 Million	339,059 Added 10.66%	3,519,462 $7.46 Million
Q3 2023 Nov 14, 2023	BUY	$2.11 - $3.28 $216,450 - $336,472	102,583 Added 3.0%	3,519,462 $7.46 Million
Q2 2023 May 14, 2024	BUY	$1.97 - $3.69 $2.01 Million - $3.76 Million	1,019,826 Added 42.54%	3,416,879 $11 Million
Q2 2023 Aug 14, 2023	BUY	$1.97 - $3.69 $2.01 Million - $3.76 Million	1,019,826 Added 42.54%	3,416,879 $11 Million
Q1 2023 May 14, 2024	BUY	$2.14 - $3.4 $2.68 Million - $4.26 Million	1,251,703 Added 109.29%	2,397,053 $5.2 Million
Q1 2023 May 11, 2023	BUY	$2.14 - $3.4 $2.68 Million - $4.26 Million	1,251,703 Added 109.29%	2,397,053 $5.2 Million
Q4 2022 May 14, 2024	BUY	$2.03 - $2.42 $441,797 - $526,674	217,634 Added 23.46%	1,145,350 $2.77 Million
Q4 2022 Feb 13, 2023	BUY	$2.03 - $2.42 $441,797 - $526,674	217,634 Added 23.46%	1,145,350 $2.77 Million
Q3 2022 May 14, 2024	BUY	$1.67 - $2.94 $296,931 - $522,740	177,803 Added 23.71%	927,716 $2.17 Million
Q3 2022 Nov 10, 2022	BUY	$1.67 - $2.94 $296,931 - $522,740	177,803 Added 23.71%	927,716 $2.17 Million
Q2 2022 May 14, 2024	SELL	$1.19 - $1.65 $2.89 Million - $4.01 Million	-2,430,490 Reduced 76.42%	749,913 $1.16 Million
Q2 2022 Aug 15, 2022	BUY	$1.19 - $1.65 $284,981 - $395,142	239,480 Added 46.92%	749,913 $1.16 Million
Q1 2022 May 16, 2022	BUY	$0.99 - $1.6 $94,730 - $153,099	95,687 Added 23.07%	510,433 $694,000
Q4 2021 Feb 14, 2022	SELL	$1.22 - $1.72 $86,761 - $122,319	-71,116 Reduced 14.64%	414,746 $506,000
Q3 2021 Nov 10, 2021	BUY	$1.2 - $1.5 $583,034 - $728,793	485,862 New	485,862 $666,000

Others Institutions Holding GERN

# of Institutions

285

Shares Held

502M

Call Options Held

643K

Put Options Held

276K

View Full List

About GERON CORP

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $423M
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

More about GERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Geron Corp Transaction History